Change of Corporate Broker

Summary by AI ^BETAClose X

Cizzle Biotechnology Holdings PLC has appointed Zeus Capital Limited as its sole Corporate Broker, effective immediately. This change in brokerage is a significant development for the company, which is focused on developing a non-invasive blood test for early lung cancer detection using the CIZ1B biomarker. The company has recently entered into commercial royalty-bearing arrangements and collaborations to advance its proprietary technology.

Disclaimer*

Cizzle Biotechnology Holdings PLC

30 June 2026

Cizzle Biotechnology Holdings plc

("Cizzle", "Cizzle Biotechnology", or the "Company")

Change of Corporate Broker

Cizzle Biotechnology is pleased to announce the appointment of Zeus Capital Limited as the Company's sole Corporate Broker with immediate effect.

Enquiries:

Cizzle Biotechnology Holdings plc	Via IFC Advisory
Allan Syms (Executive Chairman)

Allenby Capital Limited (Financial Adviser)	+44(0) 20 3328 5656
John Depasquale (Corporate Finance)
Zeus (Corporate Broker) James Hornigold, Alex Slater (Investment Banking) Nick Searle (ECM)	+44(0) 20 3829 5000
IFC Advisory Limited	+44(0) 20 3934 6632
Tim Metcalfe
Florence Staton

About Cizzle Biotechnology

The CIZ1B biomarker is a naturally occurring variant of the cell nuclear protein CIZ1, which is linked with the preservation of epigenetic integrity. CIZ1B is highly associated with the presence of early-stage lung cancer and can be measured in small quantities of blood. The Company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care. Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021.

For more information, please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END